Funding
← Back to your selection

Dawn Biopharma

Activity from announced rounds

Activity in this selectionnomura-real-estate-development-co-f095adde
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$121M
2 disclosed · full round size, not this investor’s share

By stage

Series A1
Series C+1

By primary sector

Biotech2

By country

Denmark1
United States1

Rounds

2 in this selection
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed